Antibodies to infliximab (ATI) in serum are related to secondary lack of response (LOR) to infliximab (IFX) remedy in sufferers with inflammatory bowel illness (IBD).
Objective: Peripheral blood T lymphocytosis (PBTL) is a uncommon, but poorly understood manifestations of thymoma, which is postulated to be linked with autoimmune/paraneoplastic manifestations resembling myasthenia